Who Paid My Doc
Margo Breilyn
Clinical Genetics (M.D.) Bronx, NY Medical Doctor
NPI 1932593464 CMS profile 7221440
3411 Wayne Ave Fl 9, Bronx, NY 10467
General payments
$7,898
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$1,119,998
Through program year 2025, Margo Breilyn of Bronx, NY is reported in the CMS Open Payments database as having received $7,898 across 18 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,119,998 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 78th percentile of Clinical Genetics (M.D.) profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,849 | 14 | |
| 2024 | General | $1,959 | 2 | |
| 2023 | General | $60 | 1 | |
| 2022 | General | $30 | 1 |
Beside peers
- Margo Breilyn
- Clinical Genetics (M.D.) median
- Middle half of Clinical Genetics (M.D.)
- National median
In program year 2025, general payments to Margo Breilyn were reported at $5,849. Among 315 Clinical Genetics (M.D.) profiles paid that year, the median was $255 and the middle half received between $85 and $3,583.
Show as a table
| Year | Margo Breilyn | Clinical Genetics (M.D.) median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $130 | $24–$2,691 | $163 |
| 2020 | $0 | $126 | $30–$3,700 | $114 |
| 2021 | $0 | $185 | $30–$3,777 | $132 |
| 2022 | $30 | $136 | $44–$2,749 | $149 |
| 2023 | $60 | $196 | $55–$5,220 | $160 |
| 2024 | $1,959 | $165 | $46–$3,171 | $164 |
| 2025 | $5,849 | $255 | $85–$3,583 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
95
Drug cost
$3,019,018
Branded share of claims
69.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ravicti Glycerol Phenylbutyrate | Brand | 26 | $2,338,402 | |
| Palynziq Pegvaliase-Pqpz | Brand | 13 | $493,295 | |
| Sapropterin Dihydrochloride | Generic | 16 | $158,772 | |
| Cystadane Betaine | Brand | 16 | $26,116 | |
| Levocarnitine Levocarnitine (With Sugar) | Brand | 11 | $1,933 | |
| Leucovorin Calcium | Generic | 13 | $499 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Cholbam |
|
$19 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
18 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Genetics (M.D.) in New York
Robert Desnick
Clinical Genetics (M.D.) · New York, NY
Manisha Balwani
Clinical Genetics (M.D.) · New York, NY
David Kronn
Clinical Genetics (M.D.) · Valhalla, NY
Jaya Ganesh
Clinical Genetics (M.D.) · New York, NY
Berrin Monteleone
Clinical Genetics (M.D.) · Mineola, NY
George Diaz
Clinical Genetics (M.D.) · New York, NY
Related records
Clinical Genetics (M.D.) in New York
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Genetics (M.D.)
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.